Investor Presentation

Systemic Sclerosis Overview Rare and life-threatening autoimmune disease characterized by tissue inflammation and fibrosis ~200,000 people with SSc in US, EU and Japan¹ 40-60% mortality in 10 years² 19 X 1: Health Advances, LLC; Lenabasum Commercial Market Assessment; 2: Tyndall et al, 2010 Zero SSC-specific drugs approved Lenabasum ~$1.4B - $2.2B annual potential market opportunity for lenabasum¹

View entire presentation